Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9583432 | 0.91 | HTR2A (0.38) | HTR2AMAOBMAOATAAR1HRH1 | |
| SCHEMBL8554610 | 0.85 | SIGMAR1 (0.39) | HTR2AMAOBMAOATAAR1RET | |
| SCHEMBL8556517 | 0.85 | SIGMAR1 (0.39) | HTR2AMAOBMAOATAAR1RET | |
| SCHEMBL8558686 | 0.81 | CYP3A4 (0.40) | HTR2A | |
| SCHEMBL9583897 | 0.79 | SIGMAR1 (0.39) | HTR2AMAOBMAOATAAR1RET | |
| SCHEMBL75787 | 0.78 | KDM1A (0.39) | HTR2AMAOBMAOADPP4 | |
| SCHEMBL865212 | 0.78 | ADRA2A (0.41) | HTR2AMAOBMAOA | |
| SCHEMBL3238206 | 0.75 | HTR2A (0.35) | HTR2AMAOBMAOA | |
| SCHEMBL3238183 | 0.75 | MAOA (0.65) | MAOBMAOA | |
| SCHEMBL20130556 | 0.73 | HTR2A (0.42) | HTR2AMAOBMAOATAAR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101553474-B | Imidazolidinone and imidazolidinone derivatives as 11b-HSD1 inhibitors for diabetes | HOFFMANN LA ROCHE | 2013-02-27 | — | — | CN | disclosed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| CN-101553474-A | Imidazolidinone and imidazolidinone derivatives as 11 b-HSD 1 inhibitors for diabetes | HOFFMANN LA ROCHE (CH) | 2009-10-07 | — | — | CN | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-5238955-A | Anticarcinogenic agents | ASTA PHARMA AG (DE) | 1993-08-24 | — | — | US | disclosed |
| US-5194644-A | Antitumor agents; treatment of leukemia | ASTA PHARMA AG (DE) | 1993-03-16 | — | — | US | disclosed |
| EP-0451753-A1 | In the ethylenic moiety substituted phenylalkylethylenediamine-platinum (II or IV) derivatives and phenylalkyl-ethylenediamines | ASTA Medica Aktiengesellschaft (DE) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | HTR2A 3246/4885MAOB 2163/4885MAOA 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.